The global Hydrogel-based Drug Delivery System market size is expected to be worth around US$ 20.6 billion by 2030, according to a new report by Vision Research Reports.
The global Hydrogel-based Drug Delivery System market size was valued at US$ 15.9 billion in 2020 and is anticipated to grow at a CAGR of 17.5% during forecast period 2021 to 2030.
Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/38334
Growth Factors
Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.
The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.
Report Highlights
The natural segment dominated the market for hydrogel-based drug delivery systems and accounted for the largest revenue share of 42.3% in 2020. Based on polymer origin the hydrogel can be classified into three main types natural, synthetic and hybrid. Proteins such as gelatin, lysosome, and collagen; and polysaccharides such as chitosan, hyaluronic acid, and alginate are used in the manufacturing of natural hydrogels. They have good cell adhesion properties but due to their mechanical and stability issues recently are less preferred in formulating drug delivery systems.
Hydrogel-based drug delivery systems are made of synthetic polymer and are gaining more acceptance than naturally derived polymer owing to their higher drug absorbing capacity, improved mechanical properties, enhanced lifetime, and controllable degradation features. Poly (vinyl pyrrolidone) starch, Poly (vinyl pyrrolidone), and Poly (acrylic acid) are the widely used synthetic polymer in drug delivery applications.
The ocular segment dominated the market for hydrogel-based drug delivery systems and accounted for the largest revenue share of 48.5% in 2020. Hydrogels are commonly used in ocular drug delivery applications because most of the hard and contact lenses are made of hydrogel films. So, it becomes easy to incorporate therapeutic drugs into contact lenses. Dextenza and Lacriset are hydrogel-based ocular drug delivery systems approved for clinical use. Additionally, there are numerous ongoing clinical trials specific to hydrogel contact lens-based drug delivery systems, which, in turn, is fueling the market growth. For instance, Massachusetts Eye and Ear Infirmary are conducting a clinical trial to study the delivery of dexamethasone drug through the hydrogel contact lens.
The subcutaneous drug delivery segment is expected to witness a CAGR of 10.3% in the market for hydrogel-based drug delivery systems over the forecast period. Hydrogel being biodegradable material they are extensively used in the formulation of subcutaneous drug delivery systems. The implants degrade naturally inside the body thereby the need for its surgical removal is eliminated.
North America dominated the hydrogel-based drug delivery systems market and accounted for the largest revenue share of 56.1% in 2020. The presence of efficient reimbursement that covers the cost of modern therapies, the domicile presence of hydrogel suppliers, and frequent product launches are the key factors expected to contribute to market growth in the region.
| Report Coverage | Details |
| Market Size | US$ 20.6 billion by 2030 |
| Growth Rate | CAGR of 17.5% From 2021 to 2030 |
| Base year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Polymer Origin, Delivery Route, |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | GALDERMA; Blairex Laboratories, Inc.; Johnson & Johnson; Bausch and Lomb; Medtronic; Ocular Therapeutix, Inc.; Ferring B.V.; Endo International plc; Akorn, Incorporated; Tolmar Pharmaceuticals, Inc. |
Key Players
Market Segmentation
Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38334 or call: +1 9197 992 333
Vision Research Report, Recently Announced New Report on "Smart Lock market - Global Industry Analysis,…
Vision Research Report, Recently Announced New Report on "2D barcode reader market - Global Industry…
Vision Research Report, Recently Announced New Report on "commercial refrigeration equipment market - Global Industry…
Vision Research Report, Recently Announced New Report on "Restaurant Point-of-Sale Terminal market - Global Industry…
Vision Research Report, Recently Announced New Report on "vacuum cleaner market- Global Industry Analysis, Market…
Vision Research Report, Recently Announced New Report on "household refrigerators and freezers market - Global…